After William Blair and Needham gave Autolus Therapeutics (NASDAQ: AUTL) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Mara Goldstein reiterated a Buy rating on Autolus Therapeutics today and set a price target of $24.00. The company’s shares closed last Wednesday at $9.10.
According to TipRanks.com, Goldstein is a 5-star analyst with an average return of 16.7% and a 43.8% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $23.00, which is a 148.4% upside from current levels. In a report issued on December 28, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $19.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.19 and a one-year low of $3.00. Currently, Autolus Therapeutics has an average volume of 115.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.